Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada’s Cannabis Market
Record Q4 and year-end total revenues of $23.4 million and $82.2 million, representing a 28% and 43% increase compared to the same periods in 2023. Robust growth in Q4 over Q3 2024, with total revenues increasing by 20%, operating income by 42%, Adjusted EBIT…
Author of the article:
Selected financial highlightsGNW
Article content
- Record Q4 and year-end total revenues of $23.4 million and $82.2 million, representing a 28% and 43% increase compar…